drugset / Trial / NCT06077149
Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
Non-randomizedParallel-groupSingle-blindPrevention
Summary
This clinical trial is studying the newly licensed RSV vaccines in adults over age 60 years living in long-term care facilities (nursing homes) by comparing the immune response to their vaccine to adults over age 60 years living in the community.
Timeline
- Start
- 2023-11-07
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arexvy | Vaccine | 120 ug | Intramuscular |
| Subject | RSVpreF | Vaccine | 120 ug | Intramuscular |